Endothelin-1
Endothelin-1 (ET-1)
The most potent endogenous vasoconstrictor. Endothelin receptor antagonists are FDA-approved for pulmonary arterial hypertension.
Mechanism of Action
Endothelin-1 binds to ETA and ETB receptors on vascular smooth muscle, producing potent and sustained vasoconstriction. ETB receptors on endothelium produce vasodilation via NO release.
Health Claims & Evidence
Most potent endogenous vasoconstrictor
Role in pulmonary arterial hypertension
Modulates cardiac function
Short-Term Effects
Potent vasoconstriction.
Long-Term Effects
Research use primarily.
Side Effects
Severe hypertension, reduced organ perfusion.
Contraindications
Not for self-administration.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
Endothelin: a potent vasoconstrictor peptide
Yanagisawa et al. · Nature · 1988
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on Endothelin-1 and related peptides, and prepare an educational research summary.
Explore Research